Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in recurrent ovarian cancer
NCT01536743Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2011
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib in ovarian epithelial carcinoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Biochemical response rate as determined by CA125 response at 4 weeks. Started Dec 2011; status: completed.
02
Drugs
palbociclib
03
Conditions
ovarian epithelial carcinoma
Beyond the preview
Go deeper on NCT01536743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01536743.